Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Low dose methotrexate does not increase hair fall and may reduce it.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.

Sublingual minoxidil effectively treats hair loss with mild side effects.

Oral bicalutamide is safe and effective for female hair loss.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Early treatment of fibrosing alopecia in a pattern distribution may improve outcomes.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

The Trichoscopy Derived Sinclair Scale offers a more accurate and reliable way to measure hair loss severity than the traditional visual method.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Filaggrin mutations are linked to atopic dermatitis and help explain how genetics and environment affect the disease.